Ascendis Pharma A/S's (ASND) "Outperform" Rating Reaffirmed at Royal Bank Of Canada

Key Points

• Royal Bank of Canada reaffirmed its Outperform rating on Ascendis Pharma and maintained a $290 price target, implying 6.88% upside from the previous close.
• Analyst views are broadly positive: 19 analysts rate the stock Buy and two rate it Hold, giving it a Moderate Buy consensus and an average target of $307.10. Recent target changes were mixed, with some analysts raising targets and others cutting them.
• In its latest reported quarter, Ascendis posted revenue of $387.22 million, above expectations, but earnings of $1.03 per share missed the $1.71 consensus estimate.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "outperform" rating reaffirmed by stock analysts at Royal Bank Of Canada in a report issued on Friday, Benzinga reports. They currently have a $290.00 target price on the biotechnology company's stock. Royal Bank Of Canada's price objective would indicate a potential upside of 6.88% from the stock's previous close.

Other equities research analysts also recently issued research reports about the stock. Citigroup reduced their price target on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a "buy" rating for the company in a research report on Monday, October 26th. Cantor Fitzgerald boosted their target price on shares of Ascendis Pharma A/S from $300.00 to $315.00 and gave the company an "overweight" rating in a research note on Friday. TD Cowen boosted their target price on shares of Ascendis Pharma A/S from $341.00 to $352.00 and gave the company a "buy" rating in a research note on Friday. Morgan Stanley reduced their target price on Ascendis Pharma A/S from $275.00 to $273.00 and set an "overweight" rating for the company in a report on Tuesday, September 1st. Finally, Raymond James Financial cut Ascendis Pharma A/S from a "strong-buy" rating to an "outperform" rating and set a $287.00 target price for the company. in a research report on Tuesday, September 15th. Nineteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $307.10.

Ascendis Pharma A/S Trading Up 1.6%

Shares of ASND traded up $4.25 during midday trading on Friday, hitting $271.32. The stock had a trading volume of 28,649 shares, compared to its average volume of 699,983. Ascendis Pharma A/S has a fifty-two week low of $188.08 and a fifty-two week high of $282.15. The business has a 50-day simple moving average of $242.58 and a two-hundred day simple moving average of $239.65. The firm has a market cap of $16.93 billion, a P/E ratio of 20.94 and a beta of 0.40. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The firm had revenue of $387.22 million during the quarter, compared to analysts' expectations of $376.75 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post 3.43 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Mads Bodenhoff sold 3,000 shares of the company's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares in the company, valued at $810,570. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 40.00% of the stock is currently owned by company insiders.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently made changes to their positions in ASND. Perceptive Advisors LLC grew its position in Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company's stock valued at $350,282,000 after purchasing an additional 450,000 shares in the last quarter. Sei Investments Co. increased its stake in Ascendis Pharma A/S by 24.8% in the 1st quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company's stock valued at $80,318,000 after buying an additional 69,673 shares during the period. Frazier Life Sciences Management L.P. lifted its position in Ascendis Pharma A/S by 68.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company's stock worth $60,053,000 after buying an additional 91,822 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Ascendis Pharma A/S by 27.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 227,013 shares of the biotechnology company's stock worth $51,602,000 after buying an additional 48,275 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its position in Ascendis Pharma A/S by 5.8% in the 1st quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company's stock worth $41,624,000 after buying an additional 10,000 shares in the last quarter.

Latest Ascendis Pharma A/S News

Here's some of the latest news about ASND:

• Positive Sentiment: Analysts mostly raised their targets. TD Cowen lifted its target to $352 and Cantor Fitzgerald to $315, both retaining bullish ratings. Canaccord also raised its target, to $274, while keeping a hold rating. These revisions signal improved expectations, though price targets are not guarantees. TD Cowen ratings
• Positive Sentiment: Regulatory progress could support future growth. European regulators recommended marketing authorization for TransCon CNP; Ascendis expects a European Commission decision in Q4 2026 and plans a first launch in Germany in Q1 2027. Q3 results and pipeline update
• Negative Sentiment: One target was lowered. HC Wainwright cut its target from $344 to $335, though it maintained a buy rating. HC Wainwright ratings

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.